Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Multiple Doses of Cedirogant (ABBV-157) in Subjects With Mild, Moderate and Severe Hepatic Impairment

Next Previous
Trial Profile

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Multiple Doses of Cedirogant (ABBV-157) in Subjects With Mild, Moderate and Severe Hepatic Impairment

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cedirogant (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors AbbVie

Most Recent Events

  • 31 Oct 2022 According to an Inventiva Pharma media release, the company decided to stop the development of cedirogant following the analysis of a recently concluded nonclinical toxicology study.
  • 31 Oct 2022 Status changed from recruiting to discontinued, according to an Inventiva Pharma media release.
  • 24 Jun 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top